Classification-Directed Treatment of Low Back Pain

The primary purpose of this proposal is to conduct a prospective, randomized, controlled clinical trial to examine whether or not treatment based on a person's direction-specific, impairment-based LBP classification is more effective than Non-specific treatment in improving short- (6 weeks) and long-term (6 and 12 months) outcomes in people with chronic LBP. We hypothesize that treatment based on a person's direction-specific, impairment-based LBP classification (Classification-specific) will result in better outcomes than Non-specific treatment. Our approach to classification-directed treatment is based on the proposal that a person's LBP is the result of adopting direction-specific strategies of movement and alignment of the spine which then are used repeatedly during the person's everyday activities. The exposure of spine tissue to repeated loading in the same direction across a day is proposed to accelerate the accumulation of stress, microtrauma, and eventually LBP. We also hypothesize that until the factors contributing to the use of the direction-specific strategies of the spine are modified, the LBP problem will persist or recur. Identification of homogeneous subgroups of people with LBP will enhance 1) the power of clinical trials, 2) prognosis, and 3) the ability to identify mechanisms contributing to different LBP problems.

Study Overview

Study Type

Interventional

Enrollment (Actual)

101

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • Saint Louis, Missouri, United States, 63108
        • Washington University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • People who report a history of chronic LBP for a minimum of 12 months,currently are experiencing LBP symptoms but not in an acute recurrence,
  • Between 18 and 60 years of age,
  • Able to stand and walk without assistance,
  • Able to understand and read English,
  • Able to understand and sign a consent form

Exclusion Criteria:

  • Any structural spinal deformity including scoliosis, kyphosis, or stenosis,
  • A spinal fracture or dislocation,
  • Osteoporosis,
  • Ankylosing spondylitis,
  • Rheumatoid arthritis,
  • Disc herniation,
  • Serious spinal complications such as tumor or infection,
  • Previous spinal surgery,
  • Frank neurological loss, i.e., weakness and sensory loss,
  • Pain or paresthesia below the knee,
  • Etiology of LBP other than the lumbar spine, e.g., hip joint,
  • History of neurologic disease which required hospitalization,
  • Active treatment for cancer,
  • History of unresolved cancer,
  • Pregnancy,
  • Magnified symptom behavior,
  • Worker's compensation or disability case,
  • In litigation for the LBP problem,
  • Referral from a specialized pain clinic source,
  • Spondylolisthesis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1 Classification-directed treatment
People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
Active Comparator: 2 Non-specific treatment
People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Oswestry Disability Index for Low Back Pain (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Functional limitation measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinematic measures of select movements and postures
Time Frame: Baseline, completion of treatment phase
Impairment level measure
Baseline, completion of treatment phase
Numeric pain rating scale (0-10 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Impairment level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Medication use (yes, no)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Impairment level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Days of low back pain-related time off (number)
Time Frame: Baseline, 6 months after treatment phase, 12 months after treatment phase
Impairment level measure; Question #5 from the Graded Chronic Pain Scale (Von Korff et al., Pain, 1990)
Baseline, 6 months after treatment phase, 12 months after treatment phase
Baecke Habitual Activity Measure (3-15 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Impairment level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Fear Avoidance Beliefs Questionnaire Work subscale (0-42 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Impairment level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Physical Functioning subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Role Functioning-Physical subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Bodily Pain subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 General Health subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Vitality subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Social Functioning Subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Role Functioning subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Fear Avoidance Beliefs Activity subscale (0-24 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Impairment level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
SF-36 Role Functioning-Emotional subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months, 12 months
Disability level measure
Baseline, completion of treatment phase, 6 months, 12 months
SF-36 Mental Health subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Disability level measure
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
Adherence to exercise (0-100%)
Time Frame: Second treatment visit, completion of treatment phase, 6 months after treatment phase, 12 months after treatment phase
Measure of the percentage of times the person reports adhering to performing the exercise as prescribed
Second treatment visit, completion of treatment phase, 6 months after treatment phase, 12 months after treatment phase
Adherence to training in performance of functional activities (0-100%)
Time Frame: Second treatment visit, completion of treatment phase, 6 months post-treatment phase, 12 months post-treatment phase
Measure of the percentage of times the person adhered to performing his/her functional activities as prescribed
Second treatment visit, completion of treatment phase, 6 months post-treatment phase, 12 months post-treatment phase

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Satisfaction with care (15-75 points)
Time Frame: Completion of treatment phase
Satisfaction with treatment
Completion of treatment phase

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Linda R Van Dillen, P.T., Ph.D., Washington University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2007

Primary Completion (Actual)

August 1, 2009

Study Completion (Actual)

November 1, 2010

Study Registration Dates

First Submitted

December 4, 2008

First Submitted That Met QC Criteria

December 4, 2008

First Posted (Estimate)

December 5, 2008

Study Record Updates

Last Update Posted (Estimate)

October 22, 2012

Last Update Submitted That Met QC Criteria

October 18, 2012

Last Verified

October 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HD047709-04

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe